In the in vivo experiment, the data showed that ZYHT can downregulate the protein expression of PI3K, AKT, CyclinD1, and Bcl-2 in the subcutaneous xenograft GC tumor tissues (Figures 7(a) and 7(c)). Here, BCL2 is linked to gastric cancer.